Given that CD38− cells may have higher NAD+ levels and more active SIRT1, CD34+CD38− CML stem cells might have more permissive cellular environment for acquisition of genetic mutations. The gene discussed is SIRT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.